Meanwhile, emerging translational validation from a preclinical study demonstrates that CD70-directed CAR-T cell constructs induce durable molecular remissions in CD19-negative DLBCL refractory to anti-CD19 cellular therapies, potentially through the reversal of antigen escape mechanisms via CD27 costimulatory signaling potentiation.22 In addition, up-regulated PI3K-AKT-mTOR pathways were observed in patients with disease progression. The gene discussed is AKT1; the disease is diffuse large B-cell lymphoma.